BACKGROUND AND OBJECTIVES: In our center, systemic lupus erythematosus nephritis is routinely treated with an oral cyclophosphamide (POCY) regimen. POCY is easy to administer and less expensive than intravenous cyclophosphamide (IVCY) as it is currently used in the United States; however, the use of POCY has declined in favor of IVCY. Our experience with POCY suggests that it is well tolerated and consistently associated with good long-term outcomes. Here we report this experience to build a case for maintaining POCY as a therapeutic option in lupus nephritis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This is a single-center, retrospective analysis of the outcome of 46 patients who had systemic lupus erythematosus with nephritis and were treated with POCY between 1995 and 2006. POCY was given for 2 to 4 mo at a dosage of 1.0 to 1.5 mg/kg ideal body weight. After completing POCY, the patients received either azathioprine or mycophenolate mofetil. RESULTS: Median follow-up was 23.5 mo, and median duration of POCY was 4 mo (range 1 to 16 mo). Durable complete or partial remission of proteinuria was achieved in 32 (70%) patients, whereas 5 (11%) progressed to ESRD. Outcomes were comparable in black and white individuals. Adverse effects occurred in fewer than 10% of the cohort, and only four patients discontinued POCY. CONCLUSIONS: These results suggest that sequential therapy of POCY followed by azathioprine or mycophenolate mofetil is comparable to IVCY regimens but that efficacy may not be affected by race.
BACKGROUND AND OBJECTIVES: In our center, systemic lupus erythematosus nephritis is routinely treated with an oral cyclophosphamide (POCY) regimen. POCY is easy to administer and less expensive than intravenous cyclophosphamide (IVCY) as it is currently used in the United States; however, the use of POCY has declined in favor of IVCY. Our experience with POCY suggests that it is well tolerated and consistently associated with good long-term outcomes. Here we report this experience to build a case for maintaining POCY as a therapeutic option in lupus nephritis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This is a single-center, retrospective analysis of the outcome of 46 patients who had systemic lupus erythematosus with nephritis and were treated with POCY between 1995 and 2006. POCY was given for 2 to 4 mo at a dosage of 1.0 to 1.5 mg/kg ideal body weight. After completing POCY, the patients received either azathioprine or mycophenolate mofetil. RESULTS: Median follow-up was 23.5 mo, and median duration of POCY was 4 mo (range 1 to 16 mo). Durable complete or partial remission of proteinuria was achieved in 32 (70%) patients, whereas 5 (11%) progressed to ESRD. Outcomes were comparable in black and white individuals. Adverse effects occurred in fewer than 10% of the cohort, and only four patients discontinued POCY. CONCLUSIONS: These results suggest that sequential therapy of POCY followed by azathioprine or mycophenolate mofetil is comparable to IVCY regimens but that efficacy may not be affected by race.
Authors: Gabriel Contreras; Victoriano Pardo; Baudouin Leclercq; Oliver Lenz; Elaine Tozman; Patricia O'Nan; David Roth Journal: N Engl J Med Date: 2004-03-04 Impact factor: 91.245
Authors: J P Ioannidis; K A Boki; M E Katsorida; A A Drosos; F N Skopouli; J N Boletis; H M Moutsopoulos Journal: Kidney Int Date: 2000-01 Impact factor: 10.612
Authors: T M Chan; F K Li; C S Tang; R W Wong; G X Fang; Y L Ji; C S Lau; A K Wong; M K Tong; K W Chan; K N Lai Journal: N Engl J Med Date: 2000-10-19 Impact factor: 91.245
Authors: William A Wilmer; Brad H Rovin; Christopher J Hebert; Sunil V Rao; Karen Kumor; Lee A Hebert Journal: J Am Soc Nephrol Date: 2003-12 Impact factor: 10.121
Authors: R Graham Barr; Stephen Seliger; Gerald B Appel; Ricardo Zuniga; Vivette D'Agati; Jane Salmon; Jai Radhakrishnan Journal: Nephrol Dial Transplant Date: 2003-10 Impact factor: 5.992
Authors: Saba Sajjad; Sumaira Farman; Muhammad Ahmed Saeed; Nighat Mir Ahmad; Bilal Azeem Butt Journal: Pak J Med Sci Date: 2017 Mar-Apr Impact factor: 1.088